Skip to main content
Premium Trial:

Request an Annual Quote

Nurosene Health, Ontario Institute for Cancer Research Team for Pancreatic Cancer Research

NEW YORK – Artificial intelligence technology developer Nurosene said Wednesday that it has entered into a partnership with the Ontario Institute for Cancer Research (OICR) to identify genetic biomarkers for pancreatic cancer.

Toronto-based Nurosene will be working through its NetraMark subsidiary, which provides AI technology to pharmaceutical and biotechnology researchers working on multiple disease states. Nurosene acquired NetraMark last October.

The firm said that its collaborative research with OICR will help clinicians select the most appropriate therapeutics for individual pancreatic cancer patients. The information will also inform drug discovery and development.

"Applying our technology to identify biomarkers in pancreatic cancer adds to our existing efforts in oncology," Nurosene CSO Joseph Geraci said in a statement. "We are excited to now be working with OICR on this important project that has the potential to have a significant impact on survival rates. This data can be further utilized to discover new therapeutic products in oncology with our current partners."